

## **Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities LLC**

**Leuven, BELGIË – 11 april 2024 – 19u00 CET** [Oxurion NV](#) (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving<sup>1</sup>, de volgende transparantiekennisgevingen heeft ontvangen:

Oxurion ontving op 10 april 2024 een eerste transparantiekennisgeving van Atlas Special Opportunities LLC waaruit blijkt dat het op 1 april 2024 1.630.434.782 aandelen van de toen uitstaande 9.014.821.287 aandelen bezat en dus boven de drempel (15%) kwam door de verwerving van stemrechtverlenende effecten. Zie bijlage 1.

Oxurion ontving op 10 april 2024 een tweede transparantiekennisgeving van Atlas Special Opportunities LLC waaruit blijkt dat het op 8 april 2024 886.039.886 aandelen van de toen uitstaande 9.014.821.287 aandelen bezat en dus onder de drempel (10%) kwam door de verkoop van stemrechtverlenende effecten. Zie bijlage 2.

### **Over Oxurion**

Oxurion (Euronext Brussel: OXUR) houdt zich bezig met de ontwikkeling van de volgende generatie standaard oftalmologische therapieën voor de behandeling van netvliesafwijkingen. Oxurion is gevestigd in Leuven, België. Meer informatie is beschikbaar op [www.oxurion.com](http://www.oxurion.com).

### ***Belangrijke informatie over toekomstgerichte verklaringen***

Bepaalde verklaringen in dit persbericht kunnen als "toekomstgericht" worden beschouwd. Dergelijke toekomstgerichte verklaringen zijn gebaseerd op de huidige verwachtingen en brengen dienovereenkomstig verschillende risico's en onzekerheden met zich mee en worden ze beïnvloed. Het bedrijf kan daarom geen enkele garantie geven dat dergelijke toekomstgerichte verklaringen zullen materialiseren en aanvaardt geen enkele verplichting om een toekomstgerichte verklaring bij te werken of te herzien, hetzij als gevolg van nieuwe informatie, toekomstige gebeurtenissen of enige andere reden. Aanvullende informatie over risico's en onzekerheden die van invloed zijn op het bedrijf en andere factoren die ertoe kunnen leiden dat de werkelijke resultaten wezenlijk verschillen van een toekomstgerichte verklaring, is opgenomen in het jaarverslag van het bedrijf. Dit persbericht vormt geen aanbod of uitnodiging voor de verkoop of aankoop van effecten of activa van Oxurion in enig rechtsgebied. Er mogen geen effecten van Oxurion worden aangeboden of verkocht in de Verenigde Staten zonder registratie onder de U.S. Securities Act van 1933, zoals gewijzigd, of in overeenstemming met een vrijstelling daarvan, en in overeenstemming met toepasselijke Amerikaanse effectenwetten.

**Voor meer informatie kunt u contact opnemen met:**

<u>Oxurion NV</u> Pascal Ghoson Chief Executive Officer <a href="mailto:Pascal.ghoson@oxurion.com">Pascal.ghoson@oxurion.com</a>	<u>Backstage Communication</u> Jurgen Vluijmans Partner <a href="mailto:jurgen@backstagecom.be">jurgen@backstagecom.be</a>
---	---

---

1. Artikel 14, eerste alinea, van de Wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen.

# BIJLAGE 1

DocuSign Envelope ID: 10CF88B5 0C1C-4A85-9417-56A33CD9572A



## 1) Status of the notification

Final

## 2) Issuer

Name: OXURION  
Identification number: 0881-620-924

## 3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

## 4) Notification by

A person that notifies alone

## 5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

## 6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

## 7) Date on which the threshold is crossed

01/04/2024 (DD/MM/YYYY)

## 8) Threshold that is crossed (in %)

15

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

## 9) Denominator

9,014,821,287

Please enter the denominator before filling in the data

## 10) Notified details

A) Voting rights	Previous notification # of voting rights	After the transaction			
		# of voting rights		% of voting rights	
Holder of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	0	1,630,434,782		18.09%	
<b>TOTAL</b>		<b>1,630,434,782</b>	<b>0</b>	<b>18.09%</b>	<b>0.00%</b>

Start with "groups" of holders. Add subtotals with  $\Sigma$ , and then finish with the persons who are "alone".  
For groups, start with the ultimate controlling natural person or legal entity.  
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	CALCULATE	1,630,434,782
		18.09%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder  will cease to hold / will hold again  voting rights as of  (DD/MM/YYYY)

13) Additional information

On 28 March 2024 (with settlement date on 1 April 2024), Atlas Special Opportunities LLC acquired 1,630,434,782 shares in Oxurion NV, as a result of which its shareholding decreased to 1,630,434,782 shares (= 18.09%, denominator = 9,014,821,287).

Done at  New York

On  05/04/2024 (DD/MM/YYYY)

Name & capacity  Patrick Vance, proxyholder

Signature 

For security reasons, the unsigned form in **xlsx** format should be transmitted to [trp.fin@fsm.a.be](mailto:trp.fin@fsm.a.be). You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in **PDF** format should also be transmitted.

# BIJLAGE 2

DocuSign Envelope ID: BEED37E6-F968-4E73-94E1-7D83B16E13F0

 <b>FSMA</b> FINANCIAL SERVICES AND MARKETS AUTHORITY	<b>Transparency notification</b> <b>Form TR-1 BE</b> <b>PART I</b>
--	--

1) Status of the notification

Final

2) Issuer

Name: OXURION  
 Identification number: 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

4) Notification by

A person that notifies alone

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

**i** Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

**Part II**

7) Date on which the threshold is crossed

08/04/2024 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

10

**i** If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

9,014,821,287

**i** Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification # of voting rights	After the transaction			
		# of voting rights		% of voting rights	
		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Holders of voting rights					
Atlas Special Opportunities LLC	1,630,434,782	886,039,886		9.83%	
<b>TOTAL</b>		<b>886,039,886</b>	<b>0</b>	<b>9.83%</b>	<b>0.00%</b>

**i** Start with "groups" of holders. Add subtotals with  $\Sigma$ , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction					
Holdings of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	<b>CALCULATE</b>	886,039,886
		9.83%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder  will cease to hold / will hold again  voting rights as of  (DD/MM/YYYY)

13) Additional information

On 4 April 2024 (with settlement date on 8 April 2024), Atlas Special Opportunities LLC sold 744,394,896 shares in Oxurion NV, as a result of which its shareholding decreased to 886,039,886 shares (= 9.83 %, denominator = 9,014,821,267).

Done at  New York

On  08/04/2024 (DD/MM/YYYY)

Name & capacity  Patrick Vance, proxyholder

Signature 

For security reasons, the unsigned form in **xlsx** format should be transmitted to [trp.fin@fsm.a.be](mailto:trp.fin@fsm.a.be). You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in **PDF** format should also be transmitted.